[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]
Atelerix’s lead molecules are ready for clinical development, with optimized follow-on molecules in the pipeline.
[/vc_column_text][/vc_column][/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column width=”1/2″][vc_column_text]
Active Thiol-Based Compounds (ATBCs) in Development
[/vc_column_text][vc_column_text]ATLX-0190 (D-CYSee): Targeted at respiratory and cardiovascular depression/Possibly overdose dependence addiction/End-of-life pain control
[/vc_column_text][vc_separator type=”normal”][vc_column_text]ATLX-0199 (D-CYSCYSdime – also called sudaxine): Targeted at respiratory and cardiovascular depression; other opioid-related side effects[/vc_column_text][vc_separator type=”normal”][vc_column_text]ATLX-0300 Targeted at reversal of highly potent weaponized opioids and their use by terrorists[/vc_column_text][vc_separator type=”normal”][vc_column_text]ATLX-0340 Targeted at reversal of ultra potent weaponized opioids and their use by terrorists[/vc_column_text][vc_separator type=”normal”][vc_column_text]Note: Planned initial route of administration is i.v. Routes to include include i.m., oral, nasal and sublingual[/vc_column_text][/vc_column][vc_column width=”1/4″][vc_single_image image=”98″ img_size=”full” qode_css_animation=””][vc_column_text]
ATLX-0190
(Optimized Lead)
[/vc_column_text][/vc_column][vc_column width=”1/4″][vc_single_image image=”99″ img_size=”full” qode_css_animation=””][vc_column_text]
ATLX-0199
(Optimized Lead)
[/vc_column_text][/vc_column][/vc_row]